Literature DB >> 3048492

T cell depletion in bone marrow transplantation.

C H Poynton1.   

Abstract

Prior to the introduction of T cell depletion graft-versus-host disease (GVHD) was the major cause of transplant-related mortality. Why has the remarkable technical achievement of efficient T cell depletion, which has virtually eliminated severe GVHD over the last few years, failed to reduce mortality and increase disease-free survival? This review examines the value of T cell depletion based on recent clinical experience. It surveys the directions that are being pursued in an effort to solve the problems that have arisen and indicates how this is leading to a greater understanding of the mechanisms involved in GVHD and the graft-versus-leukaemia effect.

Entities:  

Mesh:

Year:  1988        PMID: 3048492

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  An overview of bone marrow transplantation for chronic myeloid leukemia.

Authors:  M J Barnett; A C Eaves; G L Phillips
Journal:  CMAJ       Date:  1990-08-01       Impact factor: 8.262

2.  Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model.

Authors:  Rupal Pandey; Venkatesh L Hegde; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2011-06-14       Impact factor: 4.030

3.  Unrelated allogeneic bone marrow transplant in adrenoleukodystrophy using CD34+ stem cell selection.

Authors:  Anupama Borker; Lolie C Yu
Journal:  Metab Brain Dis       Date:  2002-09       Impact factor: 3.584

4.  Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Authors:  Y G Yang; B R Dey; J J Sergio; D A Pearson; M Sykes
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

5.  In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.

Authors:  M Sykes; M L Romick; K A Hoyles; D H Sachs
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.